• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Rituximab in the treatment of non-Hodgkin's lymphoma-a critical evaluation of randomized controlled trials
【24h】

Rituximab in the treatment of non-Hodgkin's lymphoma-a critical evaluation of randomized controlled trials

机译：利妥昔单抗治疗非霍奇金淋巴瘤-随机对照试验的关键评价

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: The use of rituximab has led to significant improvements in the outcome of both aggressive and indolent Non-Hodgkin's lymphoma (NHL). It is the first targeted therapy to be developed for the treatment of lymphoma which has been widely adopted. Areas covered: This paper discusses the use of rituximab in NHL, mainly concentrating on diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL), with a brief discussion about use in other types of NHL including mantle cell lymphoma (MCL). The use of rituximab in chronic lymphocytic leukemia (CLL) has been recently published in this journal by Robak (Robak T. Rituximab for chronic lymphocytic Leukemia. Expert Opin Biol. Ther. 2012;12(4):503-15). Non hematological indications for rituximab are also not discussed. A Pubmed search was conducted using key words of rituximab, DLBCL, FL, MCL, Burkitt's lymphoma and MALToma. Papers shortlisted for review included randomized control trials and scientific papers discussing CD20. Expert opinion: In conclusion this paper has critically evaluated the use of rituximab in the treatment mainly of DLBCL, FL and MCL both at diagnosis and relapsed disease, and briefly discuses its use in other subtypes of lymphoma. Rituximab has significantly improved the outcome of patients with B cell NHL, in particular those with DLBCL and FL. Patients usually tolerate the treatment well, and studies have shown it to be a cost effective treatment.
机译：简介：利妥昔单抗的使用已显着改善了侵袭性和惰性的非霍奇金淋巴瘤（NHL）的疗效。这是为淋巴瘤开发的第一个靶向治疗方法，已被广泛采用。涵盖领域：本文讨论了利妥昔单抗在NHL中的应用，主要集中在弥散性大B细胞淋巴瘤（DLBCL）和滤泡性淋巴瘤（FL），并简要讨论了在其他类型的NHL中的应用，包括套细胞淋巴瘤（MCL）。 Robak最近在该杂志上发表了利妥昔单抗在慢性淋巴细胞性白血病（CLL）中的使用（Robak T. Rituximab用于慢性淋巴细胞性白血病。ExpertOpin Biol。Ther。2012; 12（4）：503-15）。利妥昔单抗的非血液学适应症也未讨论。使用利妥昔单抗，DLBCL，FL，MCL，伯基特氏淋巴瘤和MALToma的关键词进行Pubmed搜索。入围的论文包括随机对照试验和讨论CD20的科学论文。专家意见：总之，本文已对利妥昔单抗在诊断和复发性疾病中主要用于DLBCL，FL和MCL的治疗进行了严格的评估，并简要讨论了其在其他亚型淋巴瘤中的应用。利妥昔单抗显着改善了B细胞NHL患者的预后，尤其是DLBCL和FL患者。患者通常对治疗耐受良好，研究表明这是一种经济有效的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号